AI Article Synopsis
- Methamphetamine is widely used for its euphoric effects, and the study aimed to understand how it and its metabolite, amphetamine, are excreted in urine after controlled administration.
- Participants were given low (10 mg) and high (20 mg) doses of methamphetamine, leading to varying maximum excretion rates, but no direct correlation between dosage and excretion rate was found.
- The research highlighted that methamphetamine has a long urinary elimination half-life, and slow excretion could lead to prolonged drug detection times due to an active renal excretion mechanism.
Article Abstract
Methamphetamine is widely abused for its euphoric effects. Our objectives were to characterize the urinary pharmacokinetics of methamphetamine and amphetamine after controlled methamphetamine administration to humans and to improve the interpretation of urine drug test results. Participants (n = 8) received 4 daily 10-mg (low) oral doses of sustained-release (d)-methamphetamine hydrochloride within 7 days. After 4 weeks, 5 participants received 4 daily 20-mg (high) oral doses. All urine specimens were collected during the study. Methamphetamine and amphetamine were measured by GC-MS/PCI. Maximum excretion rates ranged from 403 to 4919 microg/h for methamphetamine and 59 to 735 microg/h for amphetamine with no relationship between dose and excretion rate. The mean molar percentage of dose in the urine as total methamphetamine and amphetamine were 57.5 +/- 21.7% (low dose) and 40.9 +/- 8.5% (high dose). Mean urinary terminal elimination half-lives across doses were 23.6 +/- 6.6 hours for methamphetamine and 20.7 +/- 7.3 hours for amphetamine. Methamphetamine renal clearance across doses was 175 +/- 102 mL/min. The mean amphetamine/methamphetamine percentage ratio based on the area under the urinary excretion-time curve increased over time from 13.4 +/- 6.5% to 35.7 +/- 26.6%. Slow urinary excretion results in drug accumulation and increases in detection time windows. Our findings also support the presence of an active renal excretion mechanism for methamphetamine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00007691-200412000-00013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case report: Recurrence of psychosis after the surgical resection and radiation of a temporal lobe astrocytoma.
Front Psychiatry
January 2025
Department of Psychiatry and Behavioral Sciences, University of California, Davis Medical Center, Sacramento, CA, United States.
It is estimated that the incidence of first episode psychotic disorder is about 33 people out of 100,000 each year. Beyond primary psychotic illness (e.g.
View Article and Find Full Text PDFIs methamphetamine blood concentration in emergency department patients associated with the clinical picture?
Addiction
January 2025
Centre for Clinical Research in Emergency Medicine, Harry Perkins Institute of Medical Research, Perth, Australia.
Aims: This study aimed to describe clinical features and outcomes of patients presenting to the emergency department with analytically confirmed methamphetamine intoxication, to determine the blood concentration of methamphetamine and to test its association with clinical findings.
Design: The Western Australian Illicit Substance Evaluation (WISE) study is a prospective observational cohort study.
Setting: Royal Perth Hospital Emergency Department, Perth, Australia, between 2016 and 2018.
Background: In the United States, complete abstinence persists as the standard for demonstrating recovery success from substance use disorders (SUDs), apart from alcohol use disorder (AUD). Although the FDA has recently indicated openness for non-abstinence outcomes as treatment targets, the traditional benchmark of complete abstinence for new medications to treat SUDs remains a hurdle and overshadows other non-abstinent outcomes desired by people with SUDs (e.g.
View Article and Find Full Text PDFIdentification of Behavioral, Clinical, and Psychological Antecedents of Acute Stimulant Poisoning: Development and Implementation of a Mixed Methods Psychological Autopsy Study.
JMIR Form Res
January 2025
Center on Substance Use and Health, San Francisco Department of Public Health, San Francisco, CA, United States.
Background: Despite increasing fatal stimulant poisoning in the United States, little is understood about the mechanism of death. The psychological autopsy (PA) has long been used to distinguish the manner of death in equivocal cases, including opioid overdose, but has not been used to explicitly explore stimulant mortality.
Objective: We aimed to develop and implement a large PA study to identify antecedents of fatal stimulant poisoning, seeking to maximize data gathering and ethical interactions during the collateral interviews.
Ecstasy, molly, MDMA: What health practitioners need to know about this common recreational drug.
Dis Mon
January 2025
NYU Grossman School of Medicine, Department of Population Health, New York, NY, USA.
3,4-methylenedioxymethamphetamine (MDMA; commonly referred to as "ecstasy" or "molly") is a substituted amphetamine drug that is used recreationally for its acute psychoactive effects, including euphoria and increased energy, as well as prosocial effects such as increased empathy and feelings of closeness with others. Acute adverse effects can include hyperthermia, dehydration, bruxism, and diaphoresis. Post-intoxication phenomena may include insomnia, anhedonia, anxiety, depression, and memory impairment, which can persist for days following drug cessation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!